Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase III, open-label, mono-centre, follow-up extension study to evaluate the persistence of immune response to GSK Biologicals' HPV vaccine in healthy Chinese female subjects who received three doses of the vaccine in the HPV-058 study.

Trial Profile

A phase III, open-label, mono-centre, follow-up extension study to evaluate the persistence of immune response to GSK Biologicals' HPV vaccine in healthy Chinese female subjects who received three doses of the vaccine in the HPV-058 study.

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Aug 2018

At a glance

  • Drugs Human papillomavirus vaccine recombinant bivalent Japan Vaccine/MedImmune (Primary)
  • Indications Cervical intraepithelial neoplasia
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 25 Jul 2018 Status changed from recruiting to completed.
    • 01 Mar 2018 Status changed from not yet recruiting to recruiting.
    • 15 Feb 2018 Planned End Date changed from 16 Jul 2018 to 30 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top